Download

full announcement

UK
16 May 2017 16:17 CET

Change in composition of the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 16 May 2017 - Novo Nordisk today announced that Mary Szela steps down from Novo Nordisk's board of directors with immediate effect. The decision follows changed strategic focus for Novelion Therapeutics, a US-based rare disease company, where Ms Szela serves as CEO, which could lead to a potential conflict of interest.   

"I acknowledge and support Ms Szela's decision to step down from the Board of Directors and I would like to thank Ms Szela for her valuable contribution since joining in March 2015," said Göran Ando, chairman of the Board of Directors at Novo Nordisk.

Further information

Media:    
Anne Margrethe Hauge +45 3079 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com
     
Investors:    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Hanna Ögren +45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

Company announcement No 37 / 2017